Skip to main content
    L

    Liminatus Pharma, Inc. Class A Common Stock (LIMN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.97
    -0.02 (-0.67%)

    Market Cap: $4.02M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Liminatus Pharma, Inc. Class A Common Stock are Imunon (IMNN), Lantern Pharma (LTRN) and PharmaCyte Biotech (PMCB). By market cap, Liminatus Pharma, Inc. Class A Common Stock ranks 9th of the 13 companies on this page; Alaunos Therapeutics (TCRT) is the largest at $6.86M.

    Peer Comparison

    LIMN's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    Imunon Inc (IMNN)$4.08MN/AN/A0.0%-131.5%0.0%0.00%
    Lantern Pharma Inc (LTRN)$6.47MN/AN/A0.0%N/A0.0%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    Processa Pharmaceuticals Inc (PCSA)$5.20MN/AN/A0.0%N/A0.0%0.00%
    Calidi Biotherapeutics Inc. (CLDI)$2.29MN/AN/A0.0%N/A0.0%0.00%
    Can Fite Biopharma Ltd ADR (CANF)$4.30MN/A14.3x0.0%-156.8%0.0%0.00%
    CNS Pharmaceuticals Inc (CNSP)$4.22MN/AN/A0.0%N/A0.0%0.00%
    Traws Pharma Inc (TRAW)$3.86MN/AN/A0.0%N/A-100.0%0.00%
    Pulmatrix Inc (PULM)$4.71MN/AN/A0.0%N/A-99.9%0.00%
    Galmed Pharmaceuticals Ltd (GLMD)$4.95MN/AN/A0.0%N/A0.0%N/A
    Creative Medical Technology Holdings Inc (CELZ)$4.01MN/AN/A0.0%N/A0.0%0.00%
    Alaunos Therapeutics Inc (TCRT)$6.86MN/AN/A0.0%N/A-25.0%0.00%
    Peer median$4.26MN/A14.3x0.0%-144.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Liminatus Pharma, Inc. Class A Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Imunon Inc (IMNN)
    Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious...
    IMNN competitors
    Lantern Pharma Inc (LTRN)
    Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics...
    LTRN competitors
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    Processa Pharmaceuticals Inc (PCSA)
    Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients...
    PCSA competitors
    Calidi Biotherapeutics Inc. (CLDI)
    Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.
    CLDI competitors
    Can Fite Biopharma Ltd ADR (CANF)
    Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer...
    CNS Pharmaceuticals Inc (CNSP)
    CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central...
    CNSP competitors
    Traws Pharma Inc (TRAW)
    Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
    TRAW competitors
    Pulmatrix Inc (PULM)
    Pulmatrix, Inc., a clinical-stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases...
    PULM competitors
    Galmed Pharmaceuticals Ltd (GLMD)
    Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment of liver diseases.
    Creative Medical Technology Holdings Inc (CELZ)
    Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics...
    CELZ competitors
    Alaunos Therapeutics Inc (TCRT)
    Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring...
    TCRT competitors

    Frequently Asked Questions About LIMN

    Who are Liminatus Pharma, Inc. Class A Common Stock's main competitors?

    The companies most similar to Liminatus Pharma, Inc. Class A Common Stock include Imunon (IMNN), Lantern Pharma (LTRN), PharmaCyte Biotech (PMCB), Processa Pharmaceuticals (PCSA) and Calidi Biotherapeutics (CLDI), listed from the closest match.

    Who is Liminatus Pharma, Inc. Class A Common Stock's biggest competitor?

    Alaunos Therapeutics (TCRT) is the largest of the similar companies at $6.86M; Imunon (IMNN) is the closest match by business profile, size, sector and industry.

    How does LIMN stock compare with its competitors?

    LIMN's net margin is 0.0% against a peer median of 0.0%.

    Which of Liminatus Pharma, Inc. Class A Common Stock's competitors pays a higher dividend?

    Liminatus Pharma, Inc. Class A Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Liminatus Pharma, Inc. Class A Common Stock bigger than its competitors?

    No. Liminatus Pharma, Inc. Class A Common Stock is 9th by market cap among the 13 companies on this page; the largest is Alaunos Therapeutics (TCRT) at $6.86M.